Atlas Trials

Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC

Clinical trial NCT03813394 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03813394
Sponsor
National University Hospital, Singapore
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Locally Recurrent CancerMetastatic Nasopharyngeal Cancer
Start date
2019-05-01
Primary completion
2024-07-31
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.